4 results about "Limonoid" patented technology

The invention discloses a series of limonin compounds as well as a preparation method and application thereof. According to the invention, two limonin compounds, namely, methyl kihadanin D and kihadanin D, are extracted and separated from dried root bark of dictamnus dasycarpus, wherein the methyl kihadanin D is a limonin compound with a novel structure. The anti-inflammatory effect of the monomeric compound is evaluated by adopting LPS-induced RAW264.7 cell NO release, and the two compounds are proved to have an obvious inhibiting effect on NO release and have a great application prospect as a potential anti-inflammatory drug.

The present invention is directed to a process for obtaining phragmarin derivatives of formula 1a, e.g. from Entandrophragma caudatum seed extract, formula (1a), in multiple steps to produce therapeutically effective limonoids and limonoid-type compounds therefrom, e.g. compounds of formula (V), together with intermediate products, e.g. of formula (III).

The present application relates to the field of natural medicine, and more particularly to a limonoid compound derived from the small alligator pear and a preparation method thereof, the limonoid compound having one of the structures of Munropin G, Munropin H, Munropin I, Munropin J, Munropin K and Munropin L. The limonoid compound extracted from the small alligator pear shows specific inhibition effect on colon cancer cells, and is obviously superior to the inhibition effect on other types of tumor cells, so that the limonoid compound extracted from the small alligator pear is expected to be developed into a new drug for treating colon cancer.

This invention relates to the field of natural medicines, and particularly to a limonin compound, its preparation method, and its application. This invention provides a limonin compound having the structure shown in any of compounds 1-8. Data from the examples show that the limonin compound provided by this invention can inhibit the assembly of the NLRP3 inflammasome by inhibiting ASC oligomerization, thereby reducing the generation and release of downstream inflammatory factors and exerting an anti-inflammatory effect.